Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 8, 2006, Pages 720-724

  Ladage, Dennis ^a   Brixius, Klara ^a,b   Hoyer, Heike ^a   Steingen, Caroline ^a   Wesseling, Andreas ^a   Malan, Daniela ^b   Bloch, Wilhelm ^b   Schwinger, Robert H G ^a,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^c Klinikum Weiden   (Germany)

Author keywords

3 adrenoceptor; Endothelial nitric oxide synthase; Nebivolol; Oestrogen receptor

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; BETA 3 ADRENERGIC RECEPTOR; ESTROGEN RECEPTOR; FLUORESCEIN; FULVESTRANT; METOPROLOL; NEBIVOLOL; NITRIC OXIDE SYNTHASE; SERINE; THREONINE;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; FLUORESCENCE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; BENZOPYRANS; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME ACTIVATION; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ETHANOLAMINES; FLUORESCEIN; HUMANS; IMMUNOHISTOCHEMISTRY; INDICATORS AND REAGENTS; METOPROLOL; MICROSCOPY, FLUORESCENCE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROPANOLAMINES; PROTEIN TRANSPORT; RECEPTORS, ADRENERGIC, BETA-3; RECEPTORS, ESTROGEN; SERINE; TIME FACTORS; UMBILICAL VEINS; VASODILATOR AGENTS;

EID: 33745967267     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04424.x     Document Type: Article

References (24)

1. Brixius K, Bundkirchen A, Bolck B, Mehlhorn U, Schwinger RHG. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br. J. Pharmacol. 2001; 133: 1330-8.
2. Gao YS, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J. Cardiovasc. Pharmacol. 1991; 17: 964-9.
3. Cockcroft JR, Chowienczyk PJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: Evidence for an L-arginine/NO-dependent mechanism. J. Pharmacol. Exp. Ther. 1995; 274: 1067-71.
4. Dessy C, Saliez J, Ghisdal P et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005; 112: 1198-205.
5. Gosgnach W, Boixel C, Nevo N, Poiraud T, Michel JB. Nebivolol induces calcium-independent signaling in endothelial cells by a possible beta-adrenergic pathway. J. Cardiovasc. Pharmacol. 2001; 38: 191-9.
6. Garban HJ, Buga GM, Ignarro LJ. Estrogen receptor-mediated vascular responsiveness to nebivolol: A novel endothelium-related mechanism of therapeutic vasorelaxation. J. Cardiovasc. Pharmacol. 2004; 43: 638-44.
7. Ignarro LJ, Byrns RE, Trinh K, Sisodia M, Buga GM. Nebivolol: A selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide 2002; 7: 75-82.
8. Pasini AF, Garbin U, Nava MC et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases itric oxide by reducing its oxidative inactiation. J. Hypertens. 2005; 23: 589-96.
9. Ritter JM. Nebivolol: Endothelium-mediated vasodilating effect. J. Cardiovasc. Pharmacol. 2001; 38 (Suppl. 3): S13-16.
10. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: A novel mechanism for antihypertensive action. Circulation 2003; 107: 2747-52.
11. Mollnau H, Schulz E, Daiber A et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 615-21.
12. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Intergr. Comp. Physiol. 2003; 284: R1-12.
13. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-5.
14. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of Thr (495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ. Res. 2001; 88: E68-75.
15. Kojima H, Nakatsubo N, Kikuchi K et al. Detection and imaging of nitric oxide with novel fluorescent indicators: Diaminofluoresceins. Anal. Chem. 1998; 70: 2446-53.
16. Bloch W, Mehlhorn U, Krahwinkel A et al. Ischemia increases detectable endothelial nitric oxide synthase n rat and human myocardium. Nitric Oxide 2001; 5: 317-33.
17. Nisoli E, Tonello C, Landi M, Carruba MO. Functional studies of the first selective beta 3-adrenergic receptor antagonist SR 59230A in rat brown adipocytes. Mol. Pharmacol. 1996; 49: 7-14.
18. Lerman A, Zeiher AM. Endothelial function: Cardiac events. Circulation 2005; 111: 363-8.
19. O'Riordan E, Chen J, Brodsky SV, Smirnova I, Li H, Goligorsky MS. Endothelial cell dysfunction: The syndrome in making. Kidney Int. 2005; 67: 1654-8.
20. Drexler H. Endothelial dysfunction: Clinical implications. Prog. Cardiovasc. Dis. 1997; 39: 287-324.
21. Goldstein S. Beta-blocking drugs and coronary heart disease. Cardiovasc. Drugs Ther. 1997; 11: 219-25.
22. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br. J. Clin. Pharmacol. 1994; 38: 199-204.
23. Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol. Res. 1998; 38: 419-31.
24. Broeders MA, Doevendans PA, Bekkers BC et al. Nebivolol: A third-generation beta-blocker that augments vascular nitric oxide release: Endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000; 102: 677-84.